newsfilter
← Latest News
GlobeNewswire·

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

400mg QD 5:2 selected as azenosertib monotherapy pivotal study dose based on favorable benefit-risk profile in DENALI Part 2a, supporting advancement in registration-intended trialsDENALI Phase 2 trial topline readout